文献速递造血干细胞移植与细胞治疗

IL-6失调源于树突状细胞并通过经典信号介导移植物抗宿主病

IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling.
PubMed 文献 · Blood · 2019-01-01

该研究探讨异基因造血干细胞移植后IL-6失调的细胞来源与信号通路。发现受者树突状细胞分泌IL-6启动全身性失调,经经典信号促进供者Th17/Th22分化;阻断经典信号可长期存活且不损移植物抗白血病效应,而抑制trans信号反而加重慢性皮肤GVHD。

要点

  • 受者及供者树突状细胞是IL-6主要来源,驱动经典信号依赖的GVHD。
  • 靶向T细胞IL-6R删除经典信号可消除致病性Th17/Th22分化并长期存活。
  • 抑制经典信号不影响移植物抗白血病效应,而抑制trans信号加重慢性皮肤GVHD。

核心结论

  • IL-6经典信号及下游Th17/Th22分化是异基因造血干细胞移植后重要治疗靶点。

研究设计与样本

  • 基于异基因造血干细胞移植后GVHD模型的机制研究,涉及树突状细胞IL-6分泌及信号通路分析。

主要发现

  • 受者树突状细胞分泌IL-6启动全身性失调,靶向删除T细胞IL-6R消除致病性供者Th17/Th22分化并长期存活。
  • 植入后供者树突状细胞承担相同角色,维持经典IL-6信号依赖的GVHD反应。
  • 移植后cluster信号未激活,而可溶性gp130Fc抑制trans信号促进严重慢性皮肤GVHD。
  • trans信号抑制导致的慢性皮肤GVHD由多能Th22细胞扩增引起,可被IL-22删除或IL-6R抑制逆转。
  • 抑制IL-6经典信号不损害移植物抗白血病效应。

临床怎么用

  • 优先靶向IL-6经典信号而非trans信号,以降低GVHD且保留移植物抗白血病效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT) is characterized by interleukin-6 (IL-6) dysregulation. IL-6 can mediate effects via various pathways, including classical, trans, and cluster signaling. Given the recent availability of agents that differentially inhibit these discrete signaling cascades, understanding the source and signaling and cellular targets of this cytokine is paramount to inform the design of clinical studies. Here we demonstrate that IL-6 secretion from recipient dendritic cells (DCs) initiates the systemic dysregulation of this cytokine. Inhibition of DC-driven classical signaling after targeted IL-6 receptor (IL-6R) deletion in T cells eliminated pathogenic donor Th17/Th22 cell differentiation and resulted in long-term survival. After engraftment, donor DCs assume the same role, maintaining classical IL-6 signaling-dependent GVHD responses. Surprisingly, cluster signaling was not active after transplantation, whereas inhibition of trans signaling with soluble gp130Fc promoted severe, chronic cutaneous GVHD. The latter was a result of exaggerated polyfunctional Th22-cell expansion that was reversed by IL-22 deletion or IL-6R inhibition. Importantly, inhibition of IL-6 classical signaling did not impair the graft-versus-leukemia effect. Together, these data highlight IL-6 classical signaling and downstream Th17/Th22 differentiation as important therapeutic targets after alloSCT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wilkinson AN, Chang K, Kuns RD, et al. IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling. Blood. 2019. PMID: 31578204. doi:10.1182/blood.2019000396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。